share_log

Morgan Stanley Maintains Underweight on Invivyd, Lowers Price Target to $2

Benzinga Real-time News ·  Jan 24, 2023 08:58

Morgan Stanley analyst Matthew Harrison maintains Invivyd (NASDAQ:IVVD) with a Underweight and lowers the price target from $3 to $2.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment